Oral squamous cell carcinoma (OSCC) accounts for more than 50% of all oral malignancies, and it has a poor prognosis because therapeutic strategies have only limited effects (1). For effective prevention against this cancer, previous reports have attempted to identify genetically predisposed risk groups since a certain genetic background has been proposed to play an important role in the susceptibility to OSCC carcinogenesis (2-5).
Introduction
Oral squamous cell carcinoma (OSCC) accounts for more than 50% of all oral malignancies, and it has a poor prognosis because therapeutic strategies have only limited effects (1) . For effective prevention against this cancer, previous reports have attempted to identify genetically predisposed risk groups since a certain genetic background has been proposed to play an important role in the susceptibility to OSCC carcinogenesis (2) (3) (4) (5) .
There is substantial evidence that the activities of several drug-metabolizing enzymes are related to susceptibility to carcinogenesis in humans, including the cytochrome P450s (CYPs), glutathione S-transferases (GSTs), N-acetyltransferases (NATs) and quinone oxidoreductases (NQOs) (6) (7) (8) (9) (10) . Most chemical carcinogens in our environmental surroundings require metabolic activation by phase I drug-metabolizing enzymes, such as the CYPs, and subsequent detoxification by conjugation with the various phase II drug-metabolizing enzymes, such as the GSTs, NATs and NQOs (8) . Thus, the coordinated expression and regulation of phase I and phase II enzymes and their metabolic balance may be an important host factor in determining whether or not exposure to carcinogens results in cancer (6) .
The NQO1 gene encodes the phase II drug-metabolizing enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) and is regarded as one of the important enzymes for susceptibility to carcinogenesis (11) . It is evident that a polymorphism of the NQO1 gene caused by a C to T substitution at nucleotide position 609-bp exists, and while most people have a C at 609-bp as the wild-type genotype (wt), the nucleotide is occasionally replaced by a T as the variant genotype (vt) (12) . Furthermore, vt/vt homozygotes are believed to result in the loss of NQO1 enzyme activity (12) (13) (14) (15) (16) (17) .
The genomic mutation in NQO1 is frequently found in cancer cases such as colon (12, 13) , bladder (14) , lung cancers (17) and pediatric leukemias (16) . In addition, the mutation has been detected in fibroblasts obtained from a cancer-prone family (15) . These observations suggest that the genomic polymorphism in NQO1 could be closely related to susceptibility to general carcinogenesis. However, there is no available information about the frequency of the NQO1 polymorphism in oral cancer cases.
In this study, we investigated the incidence of the NQO1 gene polymorphism in cases with OSCC in comparison with control cases containing no malignancies in the whole body among the Japanese population. The re-sults clarify that the NQO1 polymorphism (C609T) should be regarded as one of the genetic risk factors for susceptibility to OSCC carcinogenesis. Table 1) A total of 105 patients (51 females and 54 males, mean age = 59.7) histopathologically diagnosed with primary OSCC (tongue 51, gingiva 26, buccal mucosa 16, floor of the mouth 5, others 7) were selected from patients who visited the Saitama Cancer Center Hospital and consented to participate in this study. We also collected a total of 102 control cases (53 females and 49 males, mean age = 60.3) from patients who visited the Kagoshima University Dental Hospital with complaints of non-neoplastic diseases, including mucocele, gingivitis, periodontitis, and cariogenic lesions among others. The control cases were well matched to the OSCC patients with respect to age and sex, and aside from the oral diseases, were apparently healthy. At the time of the first visitation to the Hospital, the patients were interviewed using a questionnaire provided by the Hospital and answered that they had no history of cancer diseases at any sites in the body.
Materials and methods

Patients and control cases (
With the approval of the Ethical Committees of both the Saitama Cancer Center and the Kagoshima University Dental School, genomic DNA samples of the OSCC patients and cancer-free controls were isolated from the peripheral lymphocytes in blood samples and/or a stored specimen was fixed in formalin and embedded in paraffin using ISOGEN (Wako, Tokyo) according to the manufacturer's protocol. The DNA samples were stored at -20˚C until use.
PCR-RFLP analysis
Genotyping identification of the polymorphism (C609T) in NQO1 was performed using a PCR-RFLP analysis of the genomic DNA samples from the OSCC patients and the control cases, according to the method of Traver et al. (12) . Briefly, the PCR reaction was carried out for 10 min for the initial stage at 95˚C to activate the DNA polymerase (AmpliTaq Gold TM , PE Applied Biosystems, CA), and then subjected to 35 cycles under the following conditions: 1 min denaturation at 94˚C, 1 min primer annealing at 55˚C and 1 min primer extension at 72˚C. The sense primer, 5'-TCTGTGGCTTC CAAGTCTTA, and the antisense primer, 5'-CCAAA TATTCTCCAGGCGTT, amplified a 113-bp oligonucleotide that included the region of the polymorphism (C609T). The PCR products were digested with 5 units of (Fig. 1) . The nucleotide polymorphism (C609T) of NQO1 was also confirmed by direct sequencing of the PCR products using an ABI 310 genetic analyzer (PE Applied Biosystems, CA) according to manufacturer's protocol (Fig. 2) .
Statistical analysis
Differences in the incidences of each genotype of NQO1 between the OSCC patients and the control cases were evaluated using them c 2 test. The odds ratios for each genotype between the OSCC patients and the control cases were estimated for the susceptibility to OSCC.
Results
The three NQO1 genotypes, wt/wt, wt/vt and vt/ vt, were found in 49 (48.0%), 52 (51.0%) and 1 (1.0%) individuals, respectively, in the 102 cancer-free control cases. The result was consistent with the Hardy-Weinberg equilibrium with a gene frequency of 0.698 for the wt and 0.302 for the vt, in which the relative frequencies p 2 , 2pq and q 2 of the genotypes estimated from the gene frequencies p and q must be equal to that observed. On the other hand, the wt/wt, wt/vt and vt/vt genotypes were found in 42 (40.0%), 49 (46.7%) and 14 (13.3%) individuals, respectively, in the 105 OSCC patients (Table 2) . Overall, the difference in the distribution of the vt/vt genotype between the OSCC patients and the control cases was significant (P < 0.001), and the frequency of the genotypes in the OSCC patients differed significantly from that in the control cases (P = 0.003). The odds ratio estimates revealed that individuals with the vt/vt genotype had an ~16.3-fold higher risk of developing cancer than those with the wt/wt genotype (95% confidence interval 2.1-129.5) ( Table 3) . There was no difference between the genotype frequencies with respect to sex and age in the OSCC patients and the control cases.
Discussion
NQO1, formerly referred to as DT-diaphorase (EC 1.6.99.2), is an important phase II drug-metabolizing enzyme that has attracted considerable attention due to its contradictory abilities to detoxify a number of natural and synthetic compounds and, on the other hand, to activate certain procarcinogenic agents (18, 19) . It is evident that an association between the NQO1 activity and the benzo[a]pyrene present in the environment is related to the risk of carcinogenesis (20) . Benzo[a]pyrene is a procarcinogen and a metabolic activation process producing carcinogenic metabolite(s) such as benzo[a]pyrenequinones is required for its carcinogenic effect (20, 21) . NQO1 can decrease the carcinogenic effect of this substance by catalyzing the obligatory two-electron reduction of quinones and quinonoid compounds to the readily excreted hydroquinones using either NADH or NADPH as an electron donor (22) . With respect to the role of NQO1 against benzo[a]pyrene, individual data of exposure to tobacco and alcohol were absent in this study. However, it may be the first step for extensive future cohort analysis of genes regarding the susceptibility to OSCC. A recent study showed that the point mutation C609T in codon 187 causes a single proline-to-serine amino acid substitution in NQO1 and results in the complete loss of the enzyme activity in homozygous (vt/vt) subjects while those with two wild-type alleles (wt/wt and wt/vt) have normal activity (12) . The mutation has been found in various cancer cases (12) (13) (14) (15) (16) (17) . In the present study, we have clarified the observation that the vt/vt genotype of NQO1 is much less common in cancer-free controls compared with OSCC patients (P < 0.001) and that the odds ratio against wt/wt was 16.3. Therefore, the higher OSCC risk observed in individuals with the vt/vt genotype of NQO1 may be consistent with the role of NQO1 in the metabolic detoxification of putative carcinogens for OSCC.
For a long time, attempts have been made to identify whether a given genetic background played some important roles in the susceptibility to OSCC carcinogenesis in humans (2-5). To elucidate the host genetic factors in a human disease, studies using appropriate animal models are useful and indispensable. We recently found that the Dark-Agouti (DA) strain of rats had an extremely high susceptibility to 4-nitroquinoline 1-oxide (4NQO)-induced tongue cancers, whereas the Wistar/Furth (WF) strain of rats showed much lower susceptibility (23, 24) . Furthermore, we found five quantitative trait loci, Tongue squamous cell carcinoma-1~5 (Tscc1~5), by genetic analysis using microsatellite markers of F2 progeny between DA and WF rats, and one of the most likely candidate genes for Tscc1 was NQO1 after comparison of the human and mouse synteny maps (24, 25) . NQO1 has been known as one of the major enzymes for the conversion of 4NQO to t h e m o r e a c t i v e c a r c i n o g e n i c m e t a b o l i t e, 4 -hydroxyaminoquinoline 1-oxide (26) . Our recent experiments on Tscc1~5 using congenic rats clarified that the contribution of the NQO1 of the DA allele to 4NQO-induced tongue carcinogenesis in rats was much higher than that of the WF allele (unpublished data).
At present, it is accepted that most of the carcinogens in our environment are activated mainly by a restricted number of CYPs, including CYP1A1, CYP1A2, CYP2E1 and CYP3A (7, 8) . Recently, it has been reported that polymorphisms of the CYP1A1 gene are closely related to the susceptibility to OSCC (6) . The CYP1A1 enzyme is one of the drug-metabolizing enzymes and is widely known to metabolize polycyclic aromatic hydrocarbons such as benzo[a]pyrene (27) . With regard to another major host gene yielding susceptibility to OSCC carcinogenesis, some investigators pointed out the close relationship of the mutation in GSTP1 and GSTM1 (7) (8) (9) (10) . It is an interesting hypothesis that these drug-metabolizing enzymes may synergistically contribute to the susceptibility to carcinogenesis. Further investigation into whether the genetic risk of OSCC is associated with certain combinations of NQO1 and other drug-metabolizing enzyme genes in terms of the genotype frequencies is now in progress.
In conclusion, it should be noted that knowledge of individual genetic differences, such as the polymorphism in NQO1, with respect to the susceptibility to chemical carcinogens is an important consideration in the risk assessment of OSCC in humans.
